UCSF

Trang Trinh, PharmD, MPH

Assistant Professor
Department of Clinical Pharmacy
Trinh
[email protected]
Phone: +1 415 885-3817
Fax: +1 415 476-6632
533 Parnassus Avenue, Rm 12D
UCSF Box 0622
San Francisco, CA 94143
United States

Links

UCSF Profiles

UCSF centers, institutes, and research programs

Faculty Member, Medication Outcomes Center

What I do

I am an Assistant Professor in the Department's Medication Outcomes Center. I teach epidemiology and infectious disease pharmacotherapy in the curriculum, conduct research including antibiotic comparative effectiveness and antimicrobial stewardship implementation studies, and support the Medical Center's infectious diseases and antimicrobial stewardship team in various quality improvement projects.

Departmental research area

clinical research

My research expertise

infectious disease epidemiology, risk factors and outcomes of drug-resistant bacterial infections, comparative effectiveness research

Clinical expertise

infectious diseases, antimicrobial stewardship

Degrees

MPH, Wayne State University
Fellowship, Infectious Diseases Outcomes, Wayne State University
PGY2, Infectious Diseases, University of Florida Health – Shands Hospital
PGY1, Pharmacy Practice Residency, University of Florida Health – Shands Hospital
PharmD, University of Maryland
BS, Biology, University of Florida

Biography

Trang Trinh is an Assistant Professor in the Department of Clinical Pharmacy's Medication Outcomes Center. Her research areas focus on antimicrobial stewardship interventions in ambulatory settings and pharmacoepidemiology of multidrug-resistant bacterial infections. Trang is especially interested in incorporating leadership/change management to implement effective antimicrobial stewardship and prescribing practices in ambulatory clinics and other outpatient settings, as well as applying advanced study design and statistical methods to bolster observational studies in infectious diseases.

In addition to her research focus, Trang also teaches epidemiology, study design, and infectious disease pharmacotherapy in the School of Pharmacy curriculum. She precepts and mentors pharmacy students and residents on infectious diseases research and quality improvement projects.

Research keywords

Infectious diseases, comparative effectiveness, antimicrobial stewardship, multidrug resistant bacteria, clinical epidemiology, vancomycin, Skin, Pseudomonas aeruginosa, Skin Diseases, Bacterial, Anti-Bacterial Agents, Bacterial Infections, Drug Resistance, Multiple, Bacterial, Cephalosporins, Administration, Intravenous, Cross Infection, Fosfomycin, Pneumonia, Bacterial, Gram-Positive Bacteria, Pseudomonas Infections, Gram-Negative Bacteria

Publications

Trinh TD, Strnad L, Damon L, Dzundza JH, Graff LR, Griffith LM, Hilts-Horeczko A, Olin R, Shenoy S, DeVoe C, Wang L, Rodriguez-Monguio R, Gu TM, Hampton SR, Macapinlac BAC, Yang K, Doernberg SB. Reductions in vancomycin and meropenem following the implementation of a febrile neutropenia management algorithm in hospitalized adults: An interrupted time series analysis. Infect Control Hosp Epidemiol. 2021 Jan 25; 1-8.
Jorgensen SCJ, Zasowski EJ, Trinh TD, Lagnf AM, Bhatia S, Sabagha N, Abdul-Mutakabbir JC, Alosaimy S, Mynatt RP, Davis SL, Rybak MJ. Daptomycin Plus ß-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. Clin Infect Dis. 2020 Jun 24; 71(1):1-10.
Zasowski EJ, Trinh TD, Atwan SM, Merzlyakova M, Langf AM, Bhatia S, Rybak MJ. Corrigendum to: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin. Open Forum Infect Dis. 2020 Jun; 7(6):ofaa059.
Alosaimy S, Sabagha NL, Lagnf AM, Zasowski EJ, Morrisette T, Jorgensen SCJ, Trinh TD, Mynatt RP, Rybak MJ. Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with ß-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis. Infect Dis Ther. 2020 Jun; 9(2):325-339.
Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Simon SP, Bhatia S, Melvin SM, Steed ME, Finch NA, Morrisette T, Estrada SJ, Rosenberg JR, Davis SL, Rybak MJ. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Antimicrob Agents Chemother. 2020 03 24; 64(4).
Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, Simon SP, Rosenberg JR, Steed ME, Estrada SJ, Morrisette T, Davis SL, Rybak MJ. Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam. Infect Dis Ther. 2020 Jun; 9(2):291-304.
Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, Steed ME, Simon SP, Estrada SJ, Morrisette T, Claeys KC, Rosenberg JR, Davis SL, Rybak MJ. Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infect Dis. 2019 Dec; 6(12):ofz522.
Trinh TD, Jorgensen SCJ, Zasowski EJ, Claeys KC, Lagnf AM, Estrada SJ, Delaportes DJ, Huang V, Klinker KP, Kaye KS, Davis SL, Rybak MJ. Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2019 11; 63(11).
Trinh TD, Smith JR, Rybak MJ. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide. Pharmacotherapy. 2019 11; 39(11):1077-1094.
Ho S, Nguyen L, Trinh T, MacDougall C. Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations. Curr Infect Dis Rep. 2019 Sep 09; 21(10):39.
Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ. Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus. Infect Dis Ther. 2019 Jun; 8(2):199-208.
Zasowski EJ, Trinh TD, Atwan SM, Merzlyakova M, Langf AM, Bhatia S, Rybak MJ. The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin. Open Forum Infect Dis. 2019 07; 6(7):ofz077.
Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections. Infect Dis Ther. 2018 Mar; 7(1):161-169.
Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, Rybak MJ. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. Antimicrob Agents Chemother. 2018 01; 62(1).
Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. Infect Dis Ther. 2018 Mar; 7(1):135-146.
Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Kidambi S, Davis SL, Rybak MJ. Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. Diagn Microbiol Infect Dis. 2017 Sep; 89(1):61-66.
Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother. 2017 02; 61(2).
Postgraduate training and career opportunities in infectious diseases pharmacy. Am J Health Syst Pharm. 2015 Oct 01; 72(19):1606-9.
Antimicrobial Stewardship in the Emergency Department. Infect Dis Ther. 2015 Sep; 4(Suppl 1):39-50.
Make a gift
We see a time when precise therapeutics—used safely and effectively—improve the health of people everywhere.
© 2002–2021 The Regents of the University of California